Recent Quotes (30 days)

You have no recent quotes
chg | %

Finance

Show: All - Companies - Funds
Results 1 - 40 of about 4379 companies and 244 funds for PH
Company Exchange Symbol Last price Quote change Market cap
Apple Inc. NASDAQ AAPL 140.92 -0.50 (-0.35%) 747.70B
Apple Inc. (Apple) designs, manufactures and markets mobile communication and media devices, personal computers, and portable digital music players, and a ...
Executive:
Art D. Levinson Ph.D.
Parker-Hannifin Corp NYSE PH 158.00 +0.47 (0.30%) 21.15B
Parker-Hannifin Corporation is a manufacturer of motion and control technologies and systems, providing precision engineered solutions for a range of mobile, ...
Biogen Inc NASDAQ BIIB 275.41 -2.46 (-0.89%) 59.92B
Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with ...
Executive:
Alexander J. Denner Ph.D.
P H Glatfelter Co NYSE GLT 21.86 +0.45 (2.10%) 947.32M
PH Glatfelter Company (Glatfelter) is a manufacturer of specialty papers and fiber -based engineered materials. The Company operates through three business ...
CTI BioPharma Corp NASDAQ CTIC 4.29 +0.13 (3.13%) 121.09M
CTI BioPharma Corp. (CTI) is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a ...
Executive:
Adam R. Craig MD Ph.D.
Exelixis, Inc. NASDAQ EXEL 20.31 -0.17 (-0.83%) 5.92B
Exelixis, Inc. is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care ...
Executive:
Alan M. Garber MD, Ph.D.
Gilead Sciences, Inc. NASDAQ GILD 67.49 -0.34 (-0.50%) 88.33B
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need.
Executive:
John C. Martin Ph.D.
Alphabet Inc NASDAQ GOOGL 839.65 -10.15 (-1.19%) 573.39B
Alphabet Inc. is a holding company. The Company's businesses include Google Inc. (Google) and its Internet products, such as Access, Calico, CapitalG, GV, ...
Executive:
Eric E. Schmidt Ph.D.
Celldex Therapeutics, Inc. NASDAQ CLDX 3.27 +0.03 (0.93%) 411.80M
Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy ...
Executive:
Gerald McMahon Ph.D.
Intuitive Surgical, Inc. NASDAQ ISRG 746.18 -2.13 (-0.28%) 27.49B
Intuitive Surgical, Inc. (Intuitive) designs, manufactures and markets da Vinci Surgical Systems, and related instruments and accessories. The Company's da ...
Executive:
Alan J. Levy Ph.D.
Capricor Therapeutics Inc NASDAQ CAPR 3.23 +0.05 (1.57%) 70.90M
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapeutics.
Executive:
Houman Hemmati MD, Ph.D.
Vertex Pharmaceuticals Incorporated NASDAQ VRTX 89.05 -0.99 (-1.10%) 22.12B
Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company ...
Executive:
David Altshuler MD, Ph.D.
Geron Corporation NASDAQ GERN 2.11 +0.01 (0.48%) 335.82M
Geron Corporation (Geron) is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic ...
Executive:
Andrew J. Grethlein Ph.D.
Albireo Pharma Inc NASDAQ BIOD 19.46 0.00 (0.00%) 1.25B
Albireo Pharma, Inc., formerly Biodel Inc., is a specialty biopharmaceutical company. It is focused on the development and commercialization of bile acid ...
Executive:
David Chiswell Ph.D.
Eli Lilly and Co NYSE LLY 84.42 +0.06 (0.07%) 93.85B
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: ...
Executive:
Jan M. Lundberg Ph.D.
Johnson & Johnson NYSE JNJ 125.90 -0.36 (-0.29%) 338.65B
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare ...
Executive:
Mary C. Beckerle Ph.
Ionis Pharmaceuticals Inc NASDAQ IONS 37.93 -0.21 (-0.55%) 4.68B
Ionis Pharmaceuticals, Inc. is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery ...
Executive:
Brett P. Monia Ph.D.
Momenta Pharmaceuticals, Inc. NASDAQ MNTA 13.40 -0.25 (-1.83%) 995.65M
Momenta Pharmaceuticals, Inc. is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for ...
Executive:
Ganesh Venkataraman Kaundinya Ph.D.
Amarin Corporation plc (ADR) NASDAQ AMRN 3.14 -0.04 (-1.26%) 856.97M
Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for ...
Executive:
Craig B. Granowitz MD, Ph.D.
Arena Pharmaceuticals, Inc. NASDAQ ARNA 1.45 +0.02 (1.40%) 353.46M
Arena Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing small molecule drugs across a range of therapeutic areas ...
Executive:
Harry F. Hixson Jr., Ph.D.
Show all 4379 companies »
Mutual Fund Symbol Nav Nav change
Trimark Global Balanced Class Series PH AIM45511 14.76 +0.01 (0.09%)
This Fund strives for long-term capital growth and current income by investing in a mix of equities and fixed-income securities. The equity portion is mainly ...
Trimark Global Fundamental Equity Cl PH AIM40681 18.09 -0.03 (-0.15%)
The Fund's investment objective is to achieve strong capital growth with a high degree of reliability over the long term. The Fund invests primarily in equities of ...
Trimark US Companies Class Series PH AIM40691 19.48 -0.04 (-0.19%)
The Fund's investment objective is to provide strong capital growth over the long term. The Fund invests primarily in equities of American companies. AIM is not ...
CIFM (HK) RMB Diversified Income Fund Class PH CIFM_HK_RMB_1GUSU9R 90.62 -0.05 (-0.06%)
CIFM (HK) RMB Diversified Income Fund seeks to achieve long term capital appreciation by investing in debt securities and equity securities which are ...
PH & N Canadian Equity Pension Trust SrO RBF8240 8.25 +0.05 (0.56%)
The fundamental investment objective of the fund is to provide significant long- term capital growth by investing primarily in a well-diversified portfolio of ...
Trimark Global Endeavour Class Series PH AIM41761 11.06 0.00 (-0.02%)
The Fund seeks to generate long-term capital growth by investing primarily in mid -cap equity securities from anywhere in the world.
Trimark Global Dividend Class Series PH AIM40761 10.91 -0.03 (-0.27%)
This Fund seeks to generate a total return over the long term by investing primarily in dividend-paying equity securities of companies located anywhere in the ...
Invesco International Growth Class Series PH AIM42761 10.73 +0.06 (0.52%)
The fund seeks to provide long-term capital growth by primarily investing in a diversified portfolio of international equity securities. The Fund emphasizes mid- ...
Fidelity´┐Ż Select Pharmaceuticals Portfolio FPHAX 18.07 +0.01 (0.06%)
The investment seeks capital appreciation. The fund normally invests at least 80 % of assets in companies engaged in the research, development, manufacture, ...
Glenmede Philadelphia International Fund GTIIX 13.11 +0.04 (0.31%)
The investment seeks maximum long-term total return consistent with reasonable risk to principal. The fund invests primarily in common stocks, including ...
PH&N Monthly Income Series C RBF7660 9.70 +0.01 (0.15%)
The fundamental investment objective of the Fund is to provide a relatively high monthly income that may consist of dividend income, interest income, realized ...
PH&N Dividend Income D RBF1150 104.65 +0.67 (0.64%)
To provide long-term capital growth and income by investing primarily in a well- diversified portfolio of dividend income-producing Canadian securities that have ...
ProFunds Pharmaceuticals UltraSector Fund Investor Class PHPIX 24.80 -0.12 (-0.48%)
The investment seeks daily investment results, before fees and expenses, that correspond to one and one-half times (1.5x) the daily performance of the Dow ...
RBC PH&N Monthly Income RBF501 10.75 -0.11 (-0.97%)
To provide a relatively high monthly income that may consist of dividend income, interest income, realized capital gains and a return of capital, with the potential ...
PH&N Bond D RBF1110 10.32 +0.02 (0.21%)
To provide relatively high yields and stability of capital by investing primarily in a well-diversified portfolio of fixed income securities issued by Canadian ...
Phillips, Hager & North Inflation-Linked Bond Fund Series D RBF1650 11.13 +0.04 (0.35%)
The fundamental investment objective of the Fund is to generate interest income that is hedged against inflation by investing primarily in real return bonds and ...
ProFunds Pharmaceuticals UltraSector Fund Service Class PHPSX 22.27 -0.11 (-0.49%)
The investment seeks daily investment results, before fees and expenses, that correspond to one and one-half times (1.5x) the daily performance of the Dow ...
PH&N Total Return Bond D RBF1340 11.44 +0.02 (0.16%)
To provide stability of capital and maximum total return by investing primarily in a well-diversified portfolio of Canadian fixed income securities and derivatives ...
PH&N High Yield Bond D RBF1280 12.20 -0.02 (-0.16%)
To provide a high level of income and the opportunity for capital appreciation by investing primarily in a well-diversified portfolio of fixed income securities issued ...
Philadelphia Investment Partners New Generation Fund PIPGX 9.03 0.00 (0.00%)
The investment seeks long-term capital appreciation. The fund seeks to achieve its investment objective by establishing long and short positions in equity ...
Show all 244 funds »